Hypertension 33, 10431048
doi: 10.1186/s12933-022-01474-z Summary Keywords glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, cardiovascular diseases, major adverse cardiovascular events, diabetes mellitus Citation Ferhatbegovi L, Mri D and Maci-Dankovi A (2023) The benefits of GLP1 receptors in cardiovascular diseases
Those included various baseline characteristic including demographics (age, gender, race), comorbidities (e.g., liver diseases, chronic lower respiratory diseases, diabetic complications, obesity and neoplasm), medications (e.g., insulin, metformin, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), tacrolimus, cyclosporine, mycophenolate mofetil (MMF), and corticosteroids), as well as laboratory tests and physical findings (e.g., hemoglobin, glycated hemoglobin (HbA1c) levels, lipid profile, estimated glomerular filtration rate (eGFR) and systolic blood pressure (SBP))
At the moment, there are over 27 different 45-minute workouts at F45 (with, I am told, more coming), offering the same classes at different times throughout the day
DSIP was not identified by name in the reviewed 2026 WADA list
